Clinical Trial Update: Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial update evaluating the optimal sequencing of treatments for poor-risk metastatic castration-resistant prostate cancer previously trea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Prostate Cancer Metastatic, Metastasis | Phase 2, Phase 3 | Status: COMPLETED